文献速递核素与放射性配体治疗肿瘤 PET/CT

化疗、阿比特龙和/或恩扎卢胺治疗后转移性去势抵抗性前列腺癌的PSMA靶向放射配体治疗:总生存期回顾性分析

PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-10-12

该回顾性分析纳入104例经化疗及阿比特龙和/或恩扎卢胺治疗后的转移性去势抵抗性前列腺癌患者,接受177Lu-PSMA-617放射配体治疗共351个周期。中位总生存期为56.0周(95%CI:50.5-61.5)。首周期后任何PSA下降、初始碱性磷酸酶<220 U/L及累积注射活度≥18.8 GBq与更长生存相关;PSA下降≥20.87%是多因素分析中改善总生存期的独立预后因素。

要点

  • 104例重度 pretreated mCRPC 患者接受177Lu-PSMA-617,中位OS 56.0周(95%CI 50.5-61.5)。
  • 首周期后任何PSA下降、ALP<220 U/L、累积活度≥18.8 GBq与更长生存相关。
  • PSA下降≥20.87%为多因素分析中改善OS的独立预后因素。

核心结论

  • 177Lu-PSMA-617放射配体治疗是一种新的有效治疗,似乎可延长经化疗、阿比特龙和/或恩扎卢胺治疗后的晚期mCRPC患者生存。

研究设计与样本

  • 回顾性分析,纳入104例经化疗、阿比特龙和/或恩扎卢胺治疗后的晚期转移性去势抵抗性前列腺癌患者,共接受351个周期177Lu-PSMA-617治疗。

主要发现

  • 观察期间51例(49%)患者死亡;97%有骨转移,77%有淋巴结转移,32%有内脏转移。
  • 首周期后任何PSA下降见于70例(67%),PSA下降≥50%见于34例(33%)。
  • 中位总生存期为56.0周(95%CI:50.5-61.5)。
  • 首周期后任何PSA下降、初始ALP<220 U/L、累积注射活度≥18.8 GBq与更长生存相关。
  • 逐步分析显示PSA下降≥20.87%是预示更长生存的最显著界值,多因素分析中仍为改善OS的独立预后因素。

关键数值与推荐

  • 首周期后任何PSA下降、初始ALP<220 U/L和累积注射活度≥18.8 GBq与更长生存相关。
  • PSA下降≥20.87%为多因素分析中改善OS的独立预后因素。
  • 初始PSA下降≥50%、初始LDH、内脏转移、二线化疗或既往镭-223对生存无影响。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Our aim was to evaluate overall survival and parameters prognosticating longer survival in a large and homogeneous group of patients treated with 177Lu-PSMA-617 radioligand therapy with heavily pretreated advanced metastatic castration resistant prostate cancer. METHODS: A total of 104 patients were treated with 351 cycles of 177Lu-PSMA-617. Prostate specific antigen (PSA) changes after the first cycle of therapy were documented prior to a second cycle. Patients were followed-up for overall survival (OS). Any PSA decline, PSA decline ≥50%, initial PSA, alkaline phosphatase (ALP), lactate dehydrogenase (LDH), visceral metastases and cumulative injected activity were analyzed and evaluated according to OS. Multivariable analysis with parameters with a p-value ≤0.05 in univariate analysis was performed, additionally adjusting for age and presence of visceral metastases. RESULTS: A total of 51 patients (49%) died during the observation period. The majority of patients (97%) presented with bone metastases, 77% with lymph node metastases and 32% with visceral metastases. All patients were treated with at least one line of chemotherapy. Either abiraterone or enzalutamide had been given in 100% of the patients. Any PSA decline occurred in 70 (67%) and a PSA decline ≥50% in 34 (33%) of patients after the first cycle. The median OS was 56.0 weeks (95%CI: 50.5-61.5). Initial PSA decline ≥50%, initial LDH, visceral metastases, second line chemotherapy or prior radium-223 did not have an effect on survival, whereas any initial PSA decline, initial ALP <220 U/L and cumulative injected activity ≥18.8 GBq were associated with a longer survival. A step-by-step analysis revealed a PSA decline ≥20.87% as the most noticeable cut-off prognosticating longer survival, which remained an independent prognosticator of improved OS in the multivariate analysis. CONCLUSION: 177Lu-PSMA-617 RLT is a new effective therapeutic and seems to prolong survival in patients with advanced mCRPC pretreated with chemotherapy, abiraterone and/or enzalutamide.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Rahbar K, Boegemann M, Yordanova A, et al. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival. Eur J Nucl Med Mol Imaging. 2017. PMID: 29026946. doi:10.1007/s00259-017-3848-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。